News
![Here's Why Integra LifeSciences Holdings Corp. Is Sinking Today](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Here's Why Integra LifeSciences Holdings Corp. Is Sinking Today
Shares of Integra LifeSciences (NASDAQ: IART), a medical device company that focuses on surgical products, fell as much as 11% in early morning trading on Wednesday after the release of second-quarter
![Why Dynavax Technologies Corporation Stock Is Slumping Today](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Why Dynavax Technologies Corporation Stock Is Slumping Today
Dynavax Technologies Corporation's (NASDAQ: DVAX) stock is slumping this morning after the FDA released the briefing documents for the company's experimental hepatitis B vaccine known as Heplisav-B
![Why EXACT Sciences Corporation Is Rising Today](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
Why EXACT Sciences Corporation Is Rising Today
Shares of EXACT Sciences (NASDAQ: EXAS), a company focused on colon-cancer detection, rose as much as 13% in early morning trading on Wednesday in response to reporting better-than-expected
![The 3 Hottest Marijuana Stocks Right Now](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
The 3 Hottest Marijuana Stocks Right Now
Though it probably goes without saying, it should be noted that marijuana stocks have been on fire over the trailing year. All but one of the 13 marijuana stocks with market caps above $200 million
![3 Under-the-Radar Stocks in the Healthcare Sector](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
3 Under-the-Radar Stocks in the Healthcare Sector
While large-cap stocks tend to grab more of the headlines, there's a whole universe of small-cap companies out there to consider as well. But which of those lesser-known companies are most deserving
![These 2 Pharma Giants May Be on Pfizer's M&A Radar Right Now](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
These 2 Pharma Giants May Be on Pfizer's M&A Radar Right Now
Despite overcoming a whopping $23 billion in branded patent expirations over the course of 2011 to 2016 and returning to growth on an operational basis, Wall Street thinks Pfizer (NYSE: PFE) still has
![These 2 Pharma Giants May Be on Pfizer's M&A Radar Right Now](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
These 2 Pharma Giants May Be on Pfizer's M&A Radar Right Now
Despite overcoming a whopping $23 billion in branded patent expirations over the course of 2011 to 2016 and returning to growth on an operational basis, Wall Street thinks Pfizer (NYSE: PFE) still has
![An Exciting New Drug Is in Clinical Trials for Aurinia Pharmaceuticals](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
An Exciting New Drug Is in Clinical Trials for Aurinia Pharmaceuticals
Richard Glickman was the CEO of Aspreva Pharmaceuticals, which put out CellCept, a drug that treats patient with lupus who develop kidney disease. Glickman has moved on to Aurinia Pharmaceuticals
![An Exciting New Drug Is in Clinical Trials for Aspreva Pharmaceuticals](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
An Exciting New Drug Is in Clinical Trials for Aspreva Pharmaceuticals
Richard Glickman was the CEO of Aspreva Pharmaceuticals, which put out CellCept, a drug that treats patient with lupus who develop kidney disease. Glickman has moved on to Aurinia Pharmaceuticals
![ALPHA MOS : Chiffre d'affaires du 1er semestre 2017](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
ALPHA MOS : Chiffre d'affaires du 1er semestre 2017
En M€ - Normes IFRS
Données non auditées
2017
2016
Variation
Chiffre d'affaires consolidé
2,1
3,8
-44%
Alpha MOS (Euronext Paris - Compartiment C - Code ISIN....
![Why Pacira Pharmaceuticals Shares Are Crashing 15% Today](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Why Pacira Pharmaceuticals Shares Are Crashing 15% Today
Pacira Pharmaceuticals (NASDAQ: PCRX) shares are down 15% at 12:00 p.m. EDT today following word that its pain medicine Exparel didn't perform as well as hoped in key phase 3 studies.Pacira
![Why Novavax, Inc Is Tanking Today](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
Why Novavax, Inc Is Tanking Today
After providing investors with a number of clinical updates, Novavax (NASDAQ: NVAX), a clinical-stage biotech focused on vaccines, saw its shares decline 24% as of 11:45 a.m. EDT on Tuesday.Here's a
![3 Dividend Stocks That Thrive in Bear Markets](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
3 Dividend Stocks That Thrive in Bear Markets
If you're looking to outsmart bears the next time they come knocking, you might want to consider adding PepsiCo (NYSE: PEP), Gilead Sciences (NASDAQ: GILD), and Colgate-Palmolive (NYSE: CL) to your
![3 Dividend Stocks That Thrive in Bear Markets](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
3 Dividend Stocks That Thrive in Bear Markets
If you're looking to outsmart bears the next time they come knocking, you might want to consider adding PepsiCo (NYSE: PEP), Gilead Sciences (NASDAQ: GILD), and Colgate-Palmolive (NYSE: CL) to your
![3 Dividend Stocks That Thrive in Bear Markets](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
3 Dividend Stocks That Thrive in Bear Markets
If you're looking to outsmart bears the next time they come knocking, you might want to consider adding PepsiCo (NYSE: PEP), Gilead Sciences (NASDAQ: GILD), and Colgate-Palmolive (NYSE: CL) to your
![Corning Looks to Sustain Its Momentum](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
Corning Looks to Sustain Its Momentum
Corning Incorporated (NYSE: GLW) is set to announce second-quarter 2017 results this Wednesday, July 26, 2017. With shares trading at a 10-year high after climbing more than 30% year to date as of
![Corning Looks to Sustain Its Momentum](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
Corning Looks to Sustain Its Momentum
Corning Incorporated (NYSE: GLW) is set to announce second-quarter 2017 results this Wednesday, July 26, 2017. With shares trading at a 10-year high after climbing more than 30% year to date as of
![Why Novavax Stock Spiked Today](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Why Novavax Stock Spiked Today
Shares of the clinical-stage vaccine-maker Novavax (NASDAQ: NVAX) gained as much as 18.2% today on sky-high volume. This noteworthy uptick was sparked by the anticipation surrounding the company's
![Why Reata Pharmaceuticals Is Rallying 17.5% Today](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
Why Reata Pharmaceuticals Is Rallying 17.5% Today
Reata Pharmaceuticals (NASDAQ: RETA) shares were surging 17.5% higher at 3 p.m. EST today, after the company reported that its experimental drug bardoxolone improved kidney function in patients with
![3 Things You Can Expect in Gilead Sciences' Q2 Update](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
3 Things You Can Expect in Gilead Sciences' Q2 Update
When Gilead Sciences (NASDAQ: GILD) reported its first-quarter results in May, expectations were low. The biotech didn't surprise anyone with dramatically lower revenue and earnings than the
![3 Things You Can Expect in Gilead Sciences' Q2 Update](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
3 Things You Can Expect in Gilead Sciences' Q2 Update
When Gilead Sciences (NASDAQ: GILD) reported its first-quarter results in May, expectations were low. The biotech didn't surprise anyone with dramatically lower revenue and earnings than the
![3 Things You Can Expect in Gilead Sciences' Q2 Update](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
3 Things You Can Expect in Gilead Sciences' Q2 Update
When Gilead Sciences (NASDAQ: GILD) reported its first-quarter results in May, expectations were low. The biotech didn't surprise anyone with dramatically lower revenue and earnings than the
![Why ImmunoGen, Inc. Jumped Higher Today](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
Why ImmunoGen, Inc. Jumped Higher Today
ImmunoGen (NASDAQ: IMGN) closed up 12% today on no apparent good news. In fact, there was a bit of bad news on Friday after partner Bayer revealed that anetumab ravtansine, which ImmunoGen helped
![Better Buy: Johnson & Johnson vs. AbbVie](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Better Buy: Johnson & Johnson vs. AbbVie
It's been a neck-and-neck race between Johnson & Johnson (NYSE: JNJ) and AbbVie (NYSE: ABBV) stocks so far in 2017. The two healthcare stocks are up by nearly identical levels year to date. And that's
![Better Buy: Johnson & Johnson vs. AbbVie](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Better Buy: Johnson & Johnson vs. AbbVie
It's been a neck-and-neck race between Johnson & Johnson (NYSE: JNJ) and AbbVie (NYSE: ABBV) stocks so far in 2017. The two healthcare stocks are up by nearly identical levels year to date. And that's